Yantai Dongcheng Pharmaceutical Group Co.,Ltd.

SZSE:002675 Stock Report

Market Cap: CN¥11.0b

Yantai Dongcheng Pharmaceutical GroupLtd Valuation

Is 002675 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 002675 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 002675 (CN¥13.6) is trading above our estimate of fair value (CN¥2.35)

Significantly Below Fair Value: 002675 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 002675?

Key metric: As 002675 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 002675. This is calculated by dividing 002675's market cap by their current earnings.
What is 002675's PE Ratio?
PE Ratio123.5x
EarningsCN¥90.79m
Market CapCN¥10.97b

Price to Earnings Ratio vs Peers

How does 002675's PE Ratio compare to its peers?

The above table shows the PE ratio for 002675 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average58.4x
688739 Liaoning Chengda BiotechnologyLtd
34.5xn/aCN¥11.3b
301207 Hualan Biological Vaccine
24.4x33.3%CN¥12.0b
300294 China Resources Boya Bio-pharmaceutical GroupLtd
87.5x44.4%CN¥15.4b
600645 Vcanbio Cell & Gene Engineering
87.3x23.0%CN¥9.4b
002675 Yantai Dongcheng Pharmaceutical GroupLtd
123.5x45.9%CN¥11.0b

Price-To-Earnings vs Peers: 002675 is expensive based on its Price-To-Earnings Ratio (123.5x) compared to the peer average (58.9x).

Price to Earnings Ratio vs Industry

How does 002675's PE Ratio compare vs other companies in the CN Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
002675 123.5xIndustry Avg. 36.6xNo. of Companies6PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 002675 is expensive based on its Price-To-Earnings Ratio (123.5x) compared to the CN Biotechs industry average (36.6x).

Price to Earnings Ratio vs Fair Ratio

What is 002675's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

002675 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio123.5x
Fair PE Ratio39.8x

Price-To-Earnings vs Fair Ratio: 002675 is expensive based on its Price-To-Earnings Ratio (123.5x) compared to the estimated Fair Price-To-Earnings Ratio (39.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 002675 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentCN¥13.60
CN¥15.25
+12.1%
8.2%CN¥16.50CN¥14.00n/a2
Nov ’25CN¥12.95
CN¥15.25
+17.8%
8.2%CN¥16.50CN¥14.00n/a2
Oct ’25CN¥14.10
CN¥15.25
+8.2%
8.2%CN¥16.50CN¥14.00n/a2
Jun ’25CN¥14.65
CN¥19.90
+35.8%
10.6%CN¥22.00CN¥17.80n/a2
May ’25CN¥13.83
CN¥20.30
+46.8%
8.4%CN¥22.00CN¥18.60n/a2
Apr ’25CN¥13.89
CN¥20.30
+46.1%
8.4%CN¥22.00CN¥18.60n/a2
Mar ’25CN¥15.12
CN¥20.30
+34.3%
8.4%CN¥22.00CN¥18.60n/a2
Feb ’25CN¥14.16
CN¥20.30
+43.4%
8.4%CN¥22.00CN¥18.60n/a2
Jan ’25CN¥18.33
CN¥20.30
+10.7%
8.4%CN¥22.00CN¥18.60n/a2
Dec ’24CN¥17.76
CN¥20.30
+14.3%
8.4%CN¥22.00CN¥18.60n/a2
Nov ’24CN¥18.51
CN¥20.30
+9.7%
8.4%CN¥22.00CN¥18.60CN¥12.952
Oct ’24CN¥16.63
CN¥20.30
+22.1%
8.4%CN¥22.00CN¥18.60CN¥14.102
Sep ’24CN¥14.17
CN¥20.30
+43.3%
8.4%CN¥22.00CN¥18.60CN¥11.932
Aug ’24CN¥14.85
CN¥20.95
+41.1%
5.0%CN¥22.00CN¥19.90CN¥12.442
Jul ’24CN¥14.71
CN¥20.95
+42.4%
5.0%CN¥22.00CN¥19.90CN¥12.582
Jun ’24CN¥15.37
CN¥20.95
+36.3%
5.0%CN¥22.00CN¥19.90CN¥14.652

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Dong-E-E-JiaoLtd

CN¥37.4b

Research and development, production, and sale of Ejiao and a series of Chinese patent medicines, health foods, and foods.

423

CN¥58.21

7D

-3.1%

1Y

17.4%

Sichuan Kelun Pharmaceutical

CN¥47.5b

Researches, develops, manufactures, distributes, and sells pharmaceutical products in China.

2422

CN¥29.94

7D

-9.9%

1Y

7.4%

China Resources Double-Crane PharmaceuticalLtd

CN¥22.3b

China Resources Double-Crane Pharmaceutical Co.,Ltd.

600062

CN¥21.72

7D

-1.2%

1Y

18.8%